This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IGI Laboratories Announces 2nd Quarter 2013 Results

IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the second quarter ended June 30, 2013.

Second Quarter and Year to Date 2013 Highlights
  • Total revenues of $3.8 million in the second quarter of 2013, an increase of 57% over the same quarter in 2012
  • Total revenues of $7.5 million for the six months ended June 30, 2013, an increase of 76% over the same period in 2012
  • Total revenues generated from the sale of IGI label generic topical pharmaceutical products for the three and six months ended June 30, 2013 were $1.4 million, and $2.8 million, respectively
  • Revenue from our formulation and manufacturing contract services business increased by 10% year to date in 2013 as compared to the same period in 2012
  • Gross profit increased to 30.1% for the six months ended June 30, 2013 from 28.6% in the same period of 2012
  • Filed one Abbreviated Drug Application, or ANDA, with the U.S. Food and Drug Administration (FDA) in the second quarter of 2013
  • Net loss was $0.4 million and $0.6 million in the second quarter of 2013 and 2012, respectively
  • Net loss was $0.7 million and $1.3 million for the six months ended June 30, 2013 and 2012, respectively
  • Net loss included research and development costs of $0.8 million and $0.6 million in the second quarter of 2013 and 2012, respectively

IGI’s President and Chief Executive Officer, Jason Grenfell-Gardner, stated, “I am extremely pleased with the progress we have made to obtain IGI’s current market position in our first three IGI labeled topical pharmaceutical products. We are ready to launch our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013 pending final FDA approval of our site transfer. We have expanded our IGI label customer base for our existing product lines, and we continue to explore opportunities to potentially expand our product portfolio. Our formulation and manufacturing contract services revenue continued to grow, and has increased 10% over 2012 year to date.” Mr. Grenfell-Gardner continued, “Our research and development team has filed three ANDAs in 2013, one in January, one in April, and one in July, which brings our total filings pending with the US FDA to 11. Our team is committed to our plan to file at least six ANDAs in 2013. We remain on track for our target to at least double our 2012 total revenue and achieve profitability in 2013.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.13 -1.10%
FB $117.84 0.35%
GOOG $696.48 0.60%
TSLA $226.36 -2.60%
YHOO $35.88 -0.36%


Chart of I:DJI
DOW 17,648.52 -102.39 -0.58%
S&P 500 2,051.10 -12.27 -0.59%
NASDAQ 4,732.0970 -31.1270 -0.65%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs